iSpecimen Inc. (ISPC) - רווח נקי למניה (EPS TTM)

iSpecimen Inc. (ISPC) is implementing ESG standards via its digital bioplatform, ensuring paperless documentation and cybersecurity. On GURU.Markets, the fundamental net income per share TTM reflects the current value of -50.72. Meanwhile, the business relies on a biomaterials marketplace to diversify revenue streams, while a neutral geopolitical climate in the US and EU minimizes sanction risks for this MedTech company.

Earnings per share (EPS TTM) reflects the portion of profit allocated to each ordinary share over a trailing twelve-month period. For iSpecimen Inc. (ISPC), this metric demonstrates the efficiency of biosample monetization under strict bioethical controls. By analyzing the EPS trend over the last 12 months, investors can assess the scaling pace of the digital ecosystem. The profit dynamics reveal the business's ability to overcome the slow influx of new clinics, while steady growth in this metric confirms the fundamental stability of the capital.